Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02470585 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02470585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02470585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Terminated
Start date
July 14, 2015
Completion date
October 5, 2023
Enrollment
1,140 (actual)
Sites
210

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian neoplasm